Investigational Personalized Vaccine Provides Clinical Benefit for Some Patients with Resected Head and Neck Cancers

TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10 in San Diego.

Login Or Register To Read Full Story